In 2022, clinical trials indicated that a drug called lecanemab could slow cognitive decline in people with Alzheimer’s disease. Following the publication of these results, the global Alzheimer’s community hailed lecanemab as a groundbreaking discovery. However, closer scrutiny by independent investigators revealed that the drug might significantly bene…
Substack is the home for great culture

